Press Releases

July 20, 2022
Rheos Medicines Receives FDA “Study May Proceed” Letter to Initiate Phase 1 Clinical Study Under its Investigational New Drug Application for RHX-317 for Treatment of Autoimmune and Inflammatory Diseases
May 12, 2022
Rheos Medicines CSO Dania Rabah to Deliver Keynote Address at AAPS National Biotechnology Conference
May 09, 2022
Rheos Medicines Announces Publication of New Data to Support Targeting MALT1 to Treat Autoimmune and Inflammatory Diseases
April 14, 2022
Rheos Medicines Announces New Scientific Advisory Board Members
April 14, 2022
Rheos Medicines Appoints Katerina Leftheris, Ph.D., as SVP of Drug Discovery and Nabil Uddin, Pharm.D., as VP of Strategy and Business Development
December 13, 2021
Rheos Medicines Presents New Data Supporting MALT1 Inhibition as Novel Strategy for Precision Medicine-Based Approach to Treating Chronic Graft-Versus-Host Disease
December 09, 2021
Rheos Medicines to Participate in the 2021 RBC Capital Markets Healthcare Private Company Conference
November 04, 2021
Rheos Medicines to Present Data at ASH 2021 for MALT1 Inhibition for Treatment of Graft-Versus-Host Disease
November 01, 2021
Rheos Medicines Presents Data Demonstrating Potential of MALT1 Inhibition as Novel Approach for the Treatment of Autoimmune and Inflammatory Diseases
October 27, 2021
Rheos Medicines Forms Research Collaboration with CRYOSTEM to Evaluate MALT1 Targeted Therapeutics for Graft-versus-Host-Disease
October 13, 2021
Rheos Medicines to Present Data at ACR 2021 for MALT1 Inhibitors in Autoimmune and Inflammatory Disease and Announces RHX-317 as First Development Candidate
August 09, 2021
Rheos Medicines Appoints Nirupama Subramanian as Chief Operating Officer
July 12, 2021
Rheos Medicines Appoints Industry Leader, John Davis, Jr., M.D., M.P.H., M.S., to Board of Directors
May 27, 2021
Rheos Medicines to Present at Jefferies Virtual Healthcare Conference
December 17, 2020
Rheos Medicines and PatientsLikeMe Announce Strategic Collaboration to Investigate Underlying Metabolic Drivers of Immune-Mediated Disease
October 21, 2020
Rheos Medicines Appoints Dania Rabah, Ph.D., as Chief Scientific Officer
September 28, 2020
Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit
February 18, 2020
Rheos Medicines to Present at the Cowen and Company 40^th Annual Health Care Conference
December 19, 2019
Rheos Medicines Announces Worldwide Collaboration with Roche to Discover and Develop Novel Medicines in the Field of Immunometabolism
December 12, 2019
Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of Immunometabolism to Discover and Develop Novel Medicines
October 21, 2019
Rheos Medicines Appoints Barbara S. Fox as Chief Executive Officer
March 07, 2019
Rheos Medicines to Present at the Cowen and Company 39th Annual Health Care Conference
October 10, 2018
Rheos Medicines Expands Leadership Team with Appointments of Gad Soffer as Chief Operating Officer and J. Duncan Higgons to Board of Directors
March 22, 2018
Third Rock Ventures Launches Rheos Medicines with $60 Million in Series A Funding to Harness Immunometabolism to Develop Precision Medicines for Immune-mediated Diseases